U.S., Jan. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07317700) titled 'Phase III Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis' on Dec. 19, 2025.
Brief Summary: This trial adopts a multicenter, open label, positive drug parallel controlled clinical trial design, with a planned enrollment of approximately 105 participants in the MF trial. Successful trial participants were selected and assigned to either the experimental group or the control group in a 2:1 stratified manner, with the stratification factor being the Dynamic International Prognostic Scoring System (DIPSS) prognostic grading criteria. Continuously take the test drug/control drug until it meets the withdra...